辉瑞宣布新任首席科学官兼研发总裁-动脉网

Pfizer Announces New Chief Scientific Officer and President, Research & Development

辉瑞等信源发布 2024-11-20 20:15



可切换为仅中文







Chris Boshoff to lead all Research and Development functions including Oncology

Chris Boshoff将领导包括肿瘤学在内的所有研发职能

Oncology Unit end-to-end structure to remain intact, reporting to Boshoff

肿瘤科端到端结构保持完整，向博斯霍夫报告

Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer

罗杰·丹西（Roger Dansey）将担任临时首席肿瘤官，约翰娜·本德尔（Johanna Bendell）将加入辉瑞（Pfizer）担任肿瘤首席开发官

NEW YORK--(BUSINESS WIRE)--

纽约--（商业新闻）--

Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr.

辉瑞公司（纽约证券交易所代码：PFE）今天宣布，经过全面的内部和外部选拔程序，该公司将任命医学博士克里斯·博斯霍夫（ChrisBoshoff）为首席科学官兼研发总裁，自2025年1月1日起生效。博斯霍夫博士最近担任首席肿瘤官和执行副总裁，将接替博斯霍夫博士。

Mikael Dolsten whose departure from Pfizer was announced earlier this year. In his new role, Dr. Boshoff will remain a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Dr. Albert Bourla, and he will oversee all functions of Research & Development across all therapeutic areas..

Mikael Dolsten今年早些时候宣布离开辉瑞公司。在新的职位上，博斯霍夫博士将继续担任辉瑞执行领导团队的成员，向董事长兼首席执行官阿尔伯特·博拉博士报告，他将监督所有治疗领域的研发职能。。

Pfizer’s Oncology R&D organization will maintain its fully integrated structure with Roger Dansey, M.D. serving as Interim Chief Oncology Officer, reporting to Dr. Boshoff effective January 1, 2025. Dr. Dansey will assist Dr. Boshoff in selecting a permanent Chief Oncology Officer, after which time he will retire from Pfizer.

辉瑞公司的肿瘤研发组织将保持其完全一体化的结构，医学博士罗杰·丹西（Roger Dansey）担任临时首席肿瘤官，自2025年1月1日起向博斯霍夫博士报告。Dansey博士将协助Boshoff博士选择一名永久首席肿瘤官，之后他将从辉瑞公司退休。

He will also facilitate a smooth transition of his current responsibilities to his successor, Johanna Bendell, M.D. who will be joining Pfizer from Roche in 2025 as Chief Development Officer, Oncology..

他还将推动他目前的职责顺利过渡到他的继任者Johanna Bendell，医学博士，他将于2025年从罗氏加入辉瑞，担任肿瘤学首席开发官。。

“Dr. Boshoff is the ideal leader to propel Pfizer’s R&D engine forward and transform it into a world-leading organization with a more focused strategy, driving the delivery of additional impactful breakthrough medicines with blockbuster potential,” said Dr. Bourla, Chairman and Chief Executive Officer.

董事长兼首席执行官Bourla博士说：“博斯霍夫博士是推动辉瑞研发引擎向前发展的理想领导者，并将其转变为具有更集中战略的世界领先组织，推动交付更多具有巨大潜力的有影响力的突破性药物。”。

“Chris has a compelling vision for the future of R&D at Pfizer and deep knowledge of our entire pipeline and R&D organization that positions him well to succeed. He has an impressive record of building strong teams and delivering numerous breakthrough medicines. Under Chris’ leadership, Oncology has become one of Pfizer’s most productive divisions and his continued supervision will ensure that we achieve our goal of being a global leader in oncology and other core therapeutic areas.”.

“克里斯对辉瑞公司的研发未来有着令人信服的愿景，对我们的整个管道和研发组织有着深刻的了解，这使他能够取得成功。他在建立强大的团队和提供众多突破性药物方面有着令人印象深刻的记录。在克里斯的领导下，肿瘤学已成为辉瑞公司生产力最高的部门之一，他的持续监督将确保我们实现成为肿瘤学和其他核心治疗领域全球领导者的目标。”。

During Dr. Boshoff’s more than 11 years at Pfizer, he has delivered an impressive 24 approved innovative medicines and biosimilars in more than 30 indications. Prior to becoming Chief Oncology Officer, Chris served as Chief Development Officer for Oncology and Rare Disease, and he also previously served as Head of Development Japan across all therapeutic areas.

博斯霍夫博士在辉瑞公司工作了11年多，他在30多个适应症中提供了令人印象深刻的24种经批准的创新药物和生物仿制药。在成为首席肿瘤学官之前，克里斯曾担任肿瘤学和罕见病的首席开发官，他还曾担任日本所有治疗领域的开发主管。

Before assuming leadership roles in the biopharmaceutical industry, Dr. Boshoff served as founding Director of the University College London (UCL) Cancer Institute. He earned his medical degree from University of Pretoria in South Africa, a doctorate Ph.D. from the Institute of Cancer Research in London and trained as a medical oncologist at the Royal Marsden and Royal Free Hospitals in London.

在担任生物制药行业的领导角色之前，博斯霍夫博士曾担任伦敦大学学院（UCL）癌症研究所的创始主任。他在南非比勒陀利亚大学获得医学学位，在伦敦癌症研究所获得博士学位，并在伦敦皇家马斯登医院和皇家免费医院接受肿瘤内科医师培训。

He is an elected Fellow of the U.K. Academy of Medical Sciences..

他是英国医学科学院的当选院士。。

“I am honored to be succeeding Mikael and to be taking on leadership of a combined R&D organization that includes world-class talent and capabilities, industry leading success rates and cycle times, and a promising pipeline of innovative medicines and vaccines candidates poised to have a tremendous impact for patients globally,” said Dr.

“我很荣幸能接替米凯尔，并成为一个联合研发组织的领导者，该组织包括世界一流的人才和能力，行业领先的成功率和周期时间，以及一系列有前途的创新药物和疫苗候选人，有望对全球患者产生巨大影响，”博士说。

Chris Boshoff. “I look forward to working even more closely with Albert, our executive leadership team, and our entire R&D organization to take Pfizer’s pipeline and productivity to the next level. I am confident that we can build on our long history of successes and drive even deeper focus on advancing the most impactful programs in areas of high unmet medical need that will have a meaningful impact on patients worldwide.”.

克里斯·博斯霍夫。“我期待着与阿尔伯特（Albert）、我们的执行领导团队和整个研发组织更加紧密地合作，将辉瑞的管道和生产力提升到一个新的水平。我相信，我们可以在长期成功的基础上再接再厉，更加专注于在未满足的医疗需求较高的领域推进最具影响力的项目，这将对全球患者产生重大影响。”。

After joining Pfizer through the Seagen acquisition, Dr. Roger Dansey has served as the Chief Development Officer, Oncology. At Seagen, he served as Chief Medical Officer since 2018 and interim CEO in 2022, leading clinical development efforts for PADCEV, TUKYSA, and TIVDAK, as well as securing supplemental approvals for ADCETRIS.

Roger Dansey博士通过收购Seagen加入辉瑞后，担任肿瘤学首席开发官。自2018年起，他在Seagen担任首席医疗官，2022年担任临时首席执行官，领导PADCEV，TUKYSA和TIVDAK的临床开发工作，并获得ADCETRIS的补充批准。

Previously, he led Clinical Oncology Research at Merck, overseeing KEYTRUDA®.

此前，他领导默克公司的临床肿瘤学研究，监督KEYTRUDA®。

我

(pembrolizumab) registration efforts.

（pembrolizumab）注册工作。

Dr. Johanna Bendell is currently Global Head of Oncology, Pharma Research and Early Development at Roche. Previously, she held significant roles at Sarah Cannon Research Institute, including Director of Gastrointestinal Oncology Research and Chief Development Officer. She also held positions at Duke University Medical Center and Harvard Medical School.

JohannaBendell博士目前是罗氏公司肿瘤学、制药研究和早期开发的全球负责人。。她还曾在杜克大学医学中心和哈佛医学院任职。

Johanna holds a Doctor of Medicine degree from The University of Chicago Pritzker School of Medicine and a Bachelor of Science in Biochemistry from the University of Chicago. Her medical training includes a residency at Brigham and Women's Hospital and an oncology fellowship at Dana-Farber Cancer Institute..

Johanna拥有芝加哥大学普利茨克医学院的医学博士学位和芝加哥大学的生物化学理学学士学位。她的医学培训包括在布莱根妇女医院住院，以及在达纳法伯癌症研究所获得肿瘤学奖学金。。

About Pfizer: Breakthroughs That Change Patients’ Lives

关于辉瑞：改变患者生活的突破

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

在辉瑞，我们运用科学和全球资源为人们带来治疗方法，延长并显着改善他们的生活。我们努力为包括创新药物和疫苗在内的保健产品的发现、开发和制造制定质量、安全和价值标准。

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

辉瑞公司的同事们每天都在发达市场和新兴市场开展工作，促进健康、预防、治疗和治愈，挑战我们这个时代最可怕的疾病。作为世界首屈一指的创新生物制药公司之一，我们与医疗保健提供者、政府和当地社区合作，支持和扩大全球可靠、负担得起的医疗保健服务。

For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at .

175年来，我们一直致力于为所有依赖我们的人带来改变。我们经常在我们的网站上发布对投资者可能很重要的信息。

www.Pfizer.com

In addition, to learn more, please visit us on

此外，要了解更多信息，请访问我们

www.Pfizer.com

and follow us on X at

并在X上跟踪我们

@Pfizer

@辉瑞公司

and

和

@Pfizer News,

@辉瑞新闻，

LinkedIn,

LinkedIn，

YouTube

and like us on Facebook at

就像我们在脸书上

Facebook.com/Pfizer.

Facebook.com/Pfizer。

Disclosure Notice:

披露通知：

The information contained in this release is as of November 20, 2024. The Company assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

本版本中包含的信息截至2024年11月20日。公司不承担因新信息或未来事件或发展而更新本版本中包含的前瞻性声明的义务。

This release contains forward-looking statements about, among other things, Pfizer’s research and development organization and strategy, goals, prospects, products and product pipeline, including their potential benefits and breakthrough and blockbuster potential, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

本版本包含关于辉瑞公司研发组织和战略、目标、前景、产品和产品线的前瞻性声明，包括其潜在利益、突破和巨大潜力，涉及重大风险和不确定性，可能导致实际结果与此类声明所表达或暗示的结果存在重大差异。

Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim and preliminary data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications, biologics license applications and/or emergency use authorization applications may be filed in any jurisdictions for any potential indication for Pfizer’s product candidates; whether and when any such applications that may be pending or filed for any of Pfizer’s product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, ma.

风险和不确定性包括研究和开发固有的不确定性，包括满足预期临床终点的能力，我们临床试验的开始和/或完成日期，监管提交日期，监管批准日期和/或发布日期，以及不利的新临床数据和现有临床数据的进一步分析的可能性；与中期和初步数据相关的风险；；监管机构是否会对我们临床研究的设计和结果感到满意；是否以及何时可以在任何司法管辖区提交任何药物申请，生物制剂许可证申请和/或紧急使用授权申请，以获取辉瑞候选产品的任何潜在适应症；；监管机构影响标签的决定，马萨诸塞州。

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S.

。

Securities and Exchange Commission and available at.

证券交易委员会，网址为。

www.sec.gov

and

和

www.pfizer.com

我

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

KEYTRUDA是默克夏普多姆公司的注册商标，该公司是美国新泽西州拉威市股份有限公司默克公司的子公司。

Category: Corporate, Leadership, Research

类别：企业、领导力、研究